

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-7. (Cancelled)

8. (Previously Presented) An antisense polynucleotide or small interfering RNA against a polynucleotide encoding a polypeptide selected from the group consisting of:

- (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16;
- (b) a polypeptide that comprises the amino acid sequence of SEQ ID NO: 16 in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence of SEQ ID NO: 16; and
- (c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 15, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of any one of SEQ ID NO: 16.

9. (Cancelled)

10. (Original) The small interfering RNA of claim 8, wherein the sense strand thereof comprises the nucleotide sequence of SEQ ID NO: 13.

11-18. (Cancelled)

19. (Original) A composition for treating a cell proliferative disease, said composition comprising a pharmaceutically effective amount of an antisense polynucleotide or

small interfering RNA against a polynucleotide encoding a polypeptide selected from the group consisting of:

- (a) a polypeptide that comprises the amino acid sequence of SEQ ID NO: 16;
- (b) a polypeptide that comprises the amino acid sequence of SEQ ID NO: 16 in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence of SEQ ID NO: 16; and
- (c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 15, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 16

as an active ingredient, and a pharmaceutically acceptable carrier.

20-21. (Cancelled)

22. (Previously Presented) The composition of claim 19, wherein the cell proliferative disease is cancer.